Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol. 2016;26(3):231-9. doi:10.1097/MOU.0000000000000278
Bambouskova M, Polakovicova I, Halova I, et al. New Regulatory Roles of Galectin-3 in High-Affinity IgE Receptor Signaling. Mol Cell Biol. 2016;36(9):1366-82. doi:10.1128/MCB.00064-16
Beyaz S, Mana MD, Roper J, et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature. 2016;531(7592):53-8. doi:10.1038/nature17173
Chen F, Zhang Y, Senbabaoglu Y, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016;14(10):2476-89. doi:10.1016/j.celrep.2016.02.024
Tran MT, Zsengeller ZK, Berg AH, et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. 2016;531(7595):528-32. doi:10.1038/nature17184
Yaffe MB, Gough NR. Leveraging signaling research to understand and treat disease. Sci Signal. 2016;9(421):eg4. doi:10.1126/scisignal.aaf6275
Kedersha N, Panas MD, Achorn CA, et al. G3BP-Caprin1-USP10 complexes mediate stress granule condensation and associate with 40S subunits. J Cell Biol. 2016;212(7):845-60. doi:10.1083/jcb.201508028
Börnigen D, Tyekucheva S, Wang X, et al. Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol. 2016;12(4):e1004820. doi:10.1371/journal.pcbi.1004820
Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016;2(8):1056-64. doi:10.1001/jamaoncol.2016.0509
Groner AC, Cato L, de Tribolet-Hardy J, et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. 2016;29(6):846-58. doi:10.1016/j.ccell.2016.04.012